Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments.

TL;DR: Amivantamab as discussed by the authors is a bispecific antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET) for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertions.

TL;DR: A population of splenic memory B cells that resisted rituximab through acquisition of a unique phenotype and contributed to relapses is identified, providing a new target in B cell mediated autoimmune diseases.

TL;DR: It is shown that the supplementation of serum with recombinant GoF C2 variants not only enhances the cytocidal effect of type I anti-CD20 mAbs rituximab and ofatumumab, but also lowers the threshold of mAbs necessary for the efficient lysis of tumor cells and efficiently exploits the leftovers of the drug accumulated in patients’ sera after the previous infusion.

TL;DR: This review summarizes the available data on the role of complement activation in the treatment of mature B-cell malignancies and proposes future research directions that could be useful in optimizing the efficacy of this important class of drugs.

TL;DR: Data indicate that Mylotarg is rapidly and specifically targeted to CD33(+) cells, followed by internalization and subsequent induction of cell death, which is a promising therapy in patients with acute myeloid leukemia.

TL;DR: It is shown that natalizumab exchanges Fab arms with endogenous human IgG4 in natalIZumab-treated individuals, and mutations that completely prevent Fab-arm exchange in vivo should be considered when designing therapeutic IgG 4 antibodies.

TL;DR: The finding that macrophages can phagocytize immune complexes from the surface of a cell without destroying the cell to which these complexes are attached may be important in understanding the effects of antigens and antibodies on cells participating in a humoral immune response.